RenovoRx RNXT 深 沪
等待开盘 08-24 09:30:00 美东时间
1.32
0.000
0.00%
华盛通- 最 高1.325
- 今 开1.30
- 成交量 23.33万股
- 最 低 1.25
- 昨 收 1.32
- 总市值 5957.10万
- 52周最高 1.505
- 市盈率 静 --
- 换手率 0.52%
- 52周最低 0.7006
- 委 比 -90.05%
- 总股本 4512.95万
- 历史最高 16.74
- 量 比 0.32
- 振 幅 5.68%
- 历史最低 0.5306
- 每 手 1
- 风险率 0.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RenovoRx regains Nasdaq compliance
RenovoRx (RNXT) announced on Friday that it has received a Nasdaq notification, confirming that the company has regained compliance with the minimum bid price requirement for continued listing on the ...
08-21 21:12
RenovoRx Earnings Call: Record Growth, Rising Risks
Renovorx, Inc. (($RNXT)) has held its Q2 earnings call. Read on for the main hi...
08-21 08:27
RenovoRx Regains Nasdaq Compliance on Minimum Bid Price
The latest update is out from RenovoRx ( ($RNXT) ). On December 31, 2025, Renov...
08-21 05:14
RenovoRx Says USPTO Issues Notice Of Allowance For Patent Application Titled Methods And Apparatuses For Delivery Of Therapeutic Materials For The Treatment Of Cancer
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice o...
08-20 20:34
RenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $909.000 thousand whic...
08-13 04:09
RenovoRx shares are trading higher after the company announced the first commercial clinical use of RenovoCath for drug-delivery in the treatment of a patient with sarcoma at the CARTI Cancer Center Little Rock.
RenovoRx shares are trading higher after the company announced the first commercial clinical use of RenovoCath for drug-delivery in the treatment of a patient with sarcoma at the CARTI Cancer Center Little Rock.
08-07 01:09
RenovoRx Highlights TAMP Platform in Upcoming Oncology Webinar
RenovoRx ( ($RNXT) ) has issued an update. On August 4, 2026, RenovoRx announce...
08-05 05:13
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
RenovoRx Announces Online Publication Of Abstract From Pharmacokinetic And Pharmacodynamic Sub-Study Of Ongoing Phase III TIGeR-PaC Clinical Trial In Connection With 2026 ASCO Annual Meeting
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common
05-26 20:41
RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript
RenovoRx (NASDAQ:RNXT) released first-quarter financial results and hosted an e...
05-15 05:04
